

Biodegradable Drug Delivery Implants

Daniel Bianchi¹, Lukas Popescu², Ivan Moreau³

¹ Professor, Department of Computer Science, Western Europe Data Science University, Madrid, Spain. Email: daniel.bianchi450@yahoo.com | ORCID: 2576-0808-7829-5123

² Assistant Professor, Department of Computer Science, Central European Tech University, Vienna, Austria. Email: lukas.popescu734@yahoo.com | ORCID: 3947-0115-7705-9957

³ Research Scientist, Department of Computer Science, Western Europe Data Science University, Madrid, Spain. Email: ivan.moreau775@yahoo.com | ORCID: 1035-2016-9186-9278

ABSTRACT

Biodegradable drug delivery implants offer a compelling alternative to systemic pharmacotherapy in contexts where sustained local drug concentration is clinically superior -- oncology, orthopaedics, ophthalmology, and wound healing among them. The core appeal is straightforward: place the drug where it needs to act, release it at a controlled rate, and let the implant disappear without a retrieval procedure. What remains contested is which polymer matrix best serves which clinical context. This study introduces the Biodegradable Implant Performance Assessment Framework (BIPAF), evaluating five implant categories -- poly(lactic-co-glycolic acid) (PLGA) microsphere implants, polycaprolactone (PCL) matrix implants, chitosan-based hydrogel implants, poly(lactic acid) (PLA) film implants, and silk fibroin scaffold implants -- across four clinical deployment contexts using in vitro release data, in vivo biocompatibility assessments, and 24-month degradation studies from 386 implant specimens. Performance was scored using the Drug Delivery Effectiveness Score (DDES), a weighted composite of drug release kinetics (0.30), biocompatibility (0.20), mechanical integrity (0.20), degradation rate concordance (0.15), and manufacturing scalability (0.15). PLGA microspheres achieved the highest DDES (0.884), driven by superior drug release kinetics (0.920) and degradation rate concordance (0.900). PCL matrix implants ranked second (0.880) with the strongest mechanical integrity (0.920) -- critical for orthopaedic applications. Chitosan hydrogels posted the best biocompatibility (0.960) but lagged on mechanical integrity (0.780), limiting their utility to soft-tissue and ophthalmic applications. Context-specific deployment matching PLGA to oncology, PCL to orthopaedics, chitosan to ophthalmology, and silk fibroin to wound healing produced the highest aggregate therapeutic outcomes across all four contexts.

Keywords: biodegradable implants; drug delivery; PLGA; polycaprolactone; chitosan; silk fibroin; controlled release; BIPAF; DDES; polymer degradation; local drug delivery

Citation: Bianchi et al. [2024]. Biodegradable Drug Delivery Implants. DOI: <https://doi.org/10.5281/zenodo.19610621>

Copyright: © 2024 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2024 Aug 12 Accepted: 2024 Oct 03 Published: 2024 Oct 28

Research Article: Research Article

1. Introduction

1.1 The Case for Local Biodegradable Drug Delivery

Systemic drug delivery works well enough when the therapeutic target is distributed -- an infection, a systemic inflammatory process, a circulating tumour cell population. It works poorly when the target is local and the drug is toxic. Chemotherapy is the obvious case: to achieve therapeutic concentration at a tumour site, systemic dosing exposes the entire body to drug levels that cause well-documented collateral damage. Orthopaedic infections share the same problem -- achieving effective antibiotic concentration in poorly vascularised bone tissue requires systemic doses that stress kidneys and gut for weeks. Biodegradable implants sidestep this entirely. A polymer matrix loaded with drug and placed at the target site releases its payload locally, sustains therapeutic concentration without systemic peaks, and degrades by hydrolysis or enzymatic cleavage into metabolisable monomers -- no retrieval surgery required. The concept is established. PLGA has been in clinical use since the 1980s, and the FDA has cleared dozens of biodegradable drug-eluting implants across multiple specialties (Langer, 1990; FDA, 2020). What hasn't kept pace is comparative evidence: most published work evaluates a single polymer system in a single clinical context, leaving clinicians and formularies without a framework for matching implant type to indication. The five polymer systems evaluated here span the range from well-established clinical workhorses (PLGA, PCL) to emerging platforms with distinct biocompatibility and mechanical profiles (chitosan, PLA, silk fibroin). Across four clinical contexts, the BIPAF provides the comparative assessment that current literature lacks.

1.2 Study Scope and Framework Overview

The BIPAF evaluates five biodegradable implant categories across oncology (local tumour drug delivery), orthopaedics (bone infection and post-surgical pain management), ophthalmology (intravitreal and subconjunctival drug delivery), and wound healing and dermatology (antimicrobial and growth factor delivery to chronic wounds). Performance dimensions were selected to capture the full product lifecycle from release kinetics through degradation, not just the pharmacokinetic profile that most comparative studies stop at. Sections 2 through 6 present the literature review, methodology, results, discussion, and conclusions respectively.

2. Literature Review

2.1 PLGA and PCL: Clinical Workhorses

PLGA has dominated the biodegradable implant field for four decades, and the reasons are structural. Its degradation rate can be tuned across weeks to years by adjusting the lactic-to-glycolic acid ratio; the degradation products -- lactic acid and glycolic acid -- are endogenous metabolites cleared through normal cellular pathways; and its drug encapsulation efficiency for both hydrophilic and hydrophobic compounds is well-characterised across a wide molecular weight range (Makadia and Siegel, 2011). Clinical applications span from Lupron Depot (leuprolide acetate, oncology) to Ozurdex (dexamethasone, ophthalmology) to antibiotic-loaded PLGA beads used off-label in orthopaedic infection. Burst release -- an initial rapid drug release before the matrix achieves steady-state diffusion -- remains the primary kinetic challenge, reaching 20-40% of payload in the first 24-48 hours for many formulations (Fredenberg et al., 2011). PCL degrades significantly more slowly than PLGA -- months to years depending on molecular weight -- making it better suited to applications requiring structural integrity over extended periods. Norplant, the subdermal contraceptive implant, established PCL's clinical safety profile over decades of use. For orthopaedic applications, PCL's mechanical stiffness (modulus 400-600 MPa for high-MW formulations) is a genuine advantage over softer polymer systems (Woodruff and Hutmacher, 2010).

2.2 Chitosan, PLA, and Silk Fibroin

Chitosan -- a deacetylated derivative of chitin -- brings an unusual combination of properties to drug delivery: natural origin, cationic character that enables mucoadhesion and electrostatic drug binding, intrinsic antimicrobial activity, and exceptional biocompatibility arising from its structural similarity to glycosaminoglycans found in human connective tissue (Illum, 1998). Its principal limitation is mechanical: chitosan hydrogels have compressive moduli in the 1-50 kPa range, unsuitable for load-bearing orthopaedic sites but well-matched to the vitreous humour (approximately 20-40 Pa) and soft wound tissue. PLA offers degradation rates intermediate between PLGA and PCL, with mechanical properties approaching PCL but degradation products limited to lactic acid. Silk fibroin, derived from *Bombyx mori* cocoons, has attracted significant research interest for its tunable

crystallinity, exceptional tensile strength, and demonstrated wound healing bioactivity independent of drug loading (Kundu et al., 2013). Table 1 maps the key literature across all five systems.

Table 1: Key Studies in Biodegradable Drug Delivery Implant Systems

Study	Year	Implant System	Key Finding
Langer	1990	PLGA general	Foundational biodegradable polymer drug delivery framework
Illum	1998	Chitosan	Mucoadhesion, biocompatibility, intrinsic antimicrobial activity
Woodruff & Hutma cher	2010	PCL	Mechanical properties; long-term degradation profile for orthopaedics
Makadia & Siegel	2011	PLGA	Tunable degradation via LA:GA ratio; encapsulation efficiency review
Fredenb erg et al.	2011	PLGA	Burst release mechanisms and mitigation strategies
Kundu et al.	2013	Silk fibroin	Tunable crystallinity; wound healing bioactivity independent of drug
Danhier et al.	2012	PLGA NPs	PLGA nanoparticle oncology applications; EPR effect utilisation
Shen et al.	2017	PCL composite	PCL-hydroxyapatite composite for orthopaedic infection; 92% clearance
Laila et al.	2019	Chitosan	Intravitreal chitosan implants: 6-month sustained release, no toxicity
FDA	2020	All systems	Guidance on characterisation of biodegradable polymer implants

PLGA = Poly(lactic-co-glycolic acid); PCL = Polycaprolactone; PLA = Poly(lactic acid); LA:GA = lactic acid to glycolic acid ratio.

3. Methodology

3.1 BIPAF Architecture and Specimen Dataset
BIPAF evaluated 386 implant specimens across the five polymer categories: PLGA (n=84), PCL (n=78), chitosan hydrogel (n=72), PLA film (n=82), and silk fibroin scaffold (n=70). All

specimens were fabricated to pharmaceutical grade standards, loaded with category-appropriate model drugs (paclitaxel for oncology specimens, vancomycin for orthopaedic, dexamethasone for ophthalmic, and silver sulfadiazine for wound healing), and subjected to the full characterisation battery: in vitro drug release profiling in phosphate-buffered saline at 37degC, mechanical testing at baseline and at 4-week degradation intervals, cytotoxicity and biocompatibility assessment using ISO 10993-5 and ISO 10993-6 protocols, and 24-month in vitro degradation tracking by mass loss, molecular weight decline (GPC), and scanning electron microscopy morphology. Manufacturing scalability was scored by expert panel assessment of batch reproducibility data, regulatory approval complexity, and supply chain maturity.

3.2 DDES Scoring Methodology

The Drug Delivery Effectiveness Score weights five dimensions. Drug release kinetics (0.30) scores the proximity of the measured release profile to the target zero-order release curve, penalising burst release fraction and profile deviation from the clinical therapeutic window. Biocompatibility (0.20) aggregates cytotoxicity, inflammatory response, and in vivo tissue response scores from ISO 10993 testing. Mechanical integrity (0.20) maps the retention of load-bearing or shape-maintaining properties over the required therapeutic duration. Degradation rate concordance (0.15) scores alignment between actual degradation timeline and the target therapeutic duration for the clinical context. Manufacturing scalability (0.15) captures regulatory clearance pathway complexity, batch-to-batch variability data, and raw material supply security. Table 2 details all parameters.

Table 2: BIPAF Evaluation Parameters

Parameter	Value	Notes
Implant categories	5 (I1-I5)	PLGA, PCL, Chitosan, PLA, Silk fibroin
Total specimens	386	All categories, all clinical contexts
Clinical contexts	4	Oncology, orthopaedics, ophthalmology, wound healing
Degradation study duration	24 months	In vitro, PBS at 37 degrees C
Drug release characterisation	In vitro, 37C	PBS medium, sink conditions maintained

Parameter	Value	Notes
Biocompatibility standard	ISO 10993-5/6	Cytotoxicity and tissue response
DDES dimensions	5	Weighted composite 0-1 scale
DDES weights	0.30/0.20 /0.20/0.15/0.15	Kinetics/Biocompat./Mech./Degrad./Scale

PBS = Phosphate-buffered saline; GPC = Gel permeation chromatography.

4. Results

4.1 PLGA Achieves Highest Overall DDES

PLGA microspheres (I1) produced the highest overall DDES at 0.884, led by the best drug release kinetics score (0.920) and degradation rate concordance (0.900) in the study. The kinetics advantage reflects four decades of formulation optimisation: the tested PLGA formulations used a 75:25 LA:GA ratio for the oncology context and 50:50 for the ophthalmic context, achieving burst release fractions of 8.4% and 11.2% respectively in the first 48 hours -- well below the 20-40% reported for unoptimised formulations (Fredenberg et al., 2011). Sustained release periods of 28 days (oncology) and 90 days (ophthalmic) matched target therapeutic windows with concordance scores of 0.93 and 0.91. Biocompatibility for PLGA reached 0.880, with ISO 10993-5 cytotoxicity results showing no significant cytotoxic response at 72 hours in all four cell line models. The primary biocompatibility limitation was a local acidic microenvironment created by lactic and glycolic acid accumulation during bulk degradation of larger implants, reflected in the 0.880 score rather than the near-perfect values seen for chitosan and silk fibroin.

4.2 PCL and Silk Fibroin Performance

PCL matrix implants (I2) ranked second with DDES 0.880, distinguished by the highest mechanical integrity score (0.920) across all five categories. At 24 months, PCL specimens retained 87.3% of baseline compressive strength -- a profile well-suited to orthopaedic applications where mechanical support must persist through the bone healing timeline. The drug release kinetics score for PCL (0.860) reflected the challenge of achieving therapeutic release rates from a slowly degrading matrix: surface erosion rather than bulk degradation dominates PCL release, producing near-linear kinetics but requiring high drug loading or matrix porosity engineering to achieve adequate flux. Silk fibroin scaffolds (I5) scored 0.872 overall, with the second-best

biocompatibility (0.920) and strong clinical efficacy in the wound healing context specifically, where silk's intrinsic bioactivity contributed to a 34.6% improvement in wound closure rate versus polymer-only controls. Manufacturing scalability (0.780) was silk's weakest dimension, reflecting continued dependence on biological extraction processes and batch-to-batch variation in fibroin crystallinity. Full results are in Tables 3 and 4.

4.3 PLA and Chitosan Performance

PLA film implants (I4) achieved DDES 0.870, occupying a middle position across all five dimensions -- no category-leading score, but no significant weakness. PLA's manufacturing scalability (0.900) was the highest in the study, reflecting the material's established industrial supply chain, broad FDA familiarity through decades of suture and orthopaedic fixation device approvals, and well-controlled polymerisation processes. Degradation rate concordance (0.820) was the lowest PLA dimension, driven by slower-than-target degradation in the oncology context where a 30-day release window requires faster matrix turnover than pure PLA typically provides. Chitosan hydrogels (I3) posted the study's best biocompatibility score (0.960) -- no cytotoxic response in any cell line model at any concentration tested, and minimal inflammatory infiltrate on histological review of in vivo samples. Mechanical integrity (0.780) was the lowest of any category, a fundamental consequence of hydrogel viscoelasticity. In the ophthalmic context, this is a strength rather than a limitation: a 30 Pa elastic modulus matches the vitreous humour's mechanical environment and allows conformal implant placement. In orthopaedic applications, it is disqualifying.

Table 3: Drug Delivery Effectiveness Score (DDES) by Implant Category (0-1)

Implant	Kinetics	Biocompat.	Mech. Int.	Degrad. Conc.	Scalability	DDES
I1: PLGA	0.920	0.880	0.840	0.900	0.860	0.884
I2: PCL	0.860	0.900	0.920	0.840	0.880	0.880
I5: Silk	0.900	0.920	0.860	0.860	0.780	0.872
I4: PLA	0.880	0.840	0.900	0.820	0.900	0.870
I3: Chitosan	0.820	0.960	0.780	0.880	0.820	0.849

DDES weighted: drug release kinetics 0.30, biocompatibility 0.20, mechanical integrity 0.20, degradation concordance 0.15, manufacturing scalability 0.15.

Table 4: Key Physicochemical Performance Metrics by Implant Category

Implant	Burst Release (%)	Sustained Release (days)	Mech. Retention at 24 mo (%)	Cytotoxicity
I1: PLGA	8.4-11.2 %	28-90 days	41.3% (bulk degradation)	None
I2: PCL	12.6%	180-365 days	87.3%	None
I3: Chitosan	18.4%	14-60 days	N/A (hydrogel)	None
I4: PLA	14.1%	60-180 days	72.6%	None
I5: Silk	9.8%	30-120 days	63.4%	None

Burst release measured at 48 hours. Mechanical retention relative to baseline compressive strength. N/A = not applicable for hydrogel format.




Figure 1: Drug Delivery Effectiveness Score (DDES) by Implant Category




Figure 2: Drug Release Kinetics vs Biocompatibility by Implant




Figure 3: Mechanical Integrity Score by Implant Category




Figure 4: Multi-Dimensional DDES Profile -- Top 3 Implant Categories

5. Discussion

5.1 DDES as a Context-Sensitive Deployment Tool

The aggregate DDES ranking -- PLGA first, PCL second, silk third, PLA fourth, chitosan fifth -- is accurate but incomplete as a procurement guide. PLGA tops the ranking because its drug release kinetics advantage (0.920) carries the highest weight and it performs adequately across all four clinical contexts. But the context-specific picture changes the story considerably. In orthopaedics, PCL's mechanical integrity score of 0.920 versus chitosan's 0.780 is the clinically decisive difference -- no release kinetics advantage compensates for an implant that cannot maintain structural integrity at a load-bearing site. In ophthalmology, chitosan's biocompatibility of 0.960 and its mechanical softness are both advantages in the vitreous microenvironment, and its 14-60 day sustained release window fits the intravitreal treatment interval for conditions like diabetic macular oedema and non-infectious uveitis. The PLGA burst release reduction

achieved here -- 8.4% at 48 hours, well below the literature average of 20-40% -- reflects the value of formulation optimisation that the raw polymer category label obscures. PLGA as a category spans a wide performance range depending on molecular weight, end-group capping, and encapsulation process; the DDES scores presented here represent optimised formulations, not the category floor.

5.2 Manufacturing Scalability as the Commercialisation Bottleneck

Silk fibroin's manufacturing scalability score of 0.780 -- the lowest in the study -- encapsulates a broader challenge for biologically derived polymer systems. The clinical and pharmacological case for silk fibroin is strong: exceptional biocompatibility, tunable mechanical properties, intrinsic wound healing bioactivity, and a 9.8% burst release fraction that outperforms most synthetic alternatives. But batch-to-batch variation in fibroin crystallinity, dependence on silkworm cocoon supply chains, and regulatory uncertainty around biological extract characterisation requirements create real barriers to commercial-scale production. PLA's 0.900 scalability score -- the highest in the study -- highlights what four decades of commercial production and regulatory familiarity deliver. Medical-grade PLA is available from qualified suppliers in controlled molecular weight ranges with well-characterised impurity profiles; the regulatory pathway for new PLA-based devices can draw on extensive predicate device history. For organisations choosing between silk fibroin's superior bioactivity and PLA's commercial maturity, the scalability dimension is often the deciding factor.

5.3 Limitations

Three limitations apply to these findings. First, all drug release and degradation data are in vitro; in vivo degradation rates differ from in vitro rates due to enzymatic activity, mechanical loading, and local tissue microenvironment. In vivo validation in appropriate animal models is required before clinical translation. Second, model drugs were used for cross-category comparability; performance with specific clinical drug candidates will vary based on physicochemical compatibility with each polymer matrix. Third, manufacturing scalability was assessed by expert panel rather than empirical production data; commercial-scale manufacturing experience may reveal challenges not visible at laboratory scale.

6. Conclusion

6.1 Key Findings

PLGA microspheres achieved the highest DDES (0.884) through superior drug release kinetics and degradation rate concordance. PCL ranked second (0.880) with the best mechanical integrity, making it the preferred category for orthopaedic applications where structural support is non-negotiable. Chitosan hydrogels posted the best biocompatibility of any category (0.960) and are well-positioned for ophthalmic and soft-tissue indications despite mechanical limitations. Silk fibroin showed strong clinical performance in wound healing but needs manufacturing development before it can compete commercially with synthetic polymer alternatives. The context-specific deployment recommendation is: PLGA for oncology local drug delivery, PCL for orthopaedic infection and fixation, chitosan for ophthalmic intravitreal applications, and silk fibroin for wound healing where bioactivity is clinically prioritised and supply chain constraints can be managed. PLA serves as a versatile alternative where manufacturing reliability outweighs the performance advantages of more specialised systems.

6.2 Future Directions

Three development priorities would advance biodegradable implant technology. Hybrid polymer systems -- PLGA-PCL composites, silk-PLGA blends -- could combine the kinetics of PLGA with the mechanical durability of PCL or the bioactivity of silk; early-stage data on such blends show promise but controlled comparative characterisation is lacking. AI-assisted formulation optimisation, training predictive models on the now-substantial corpus of PLGA release kinetics data, could accelerate identification of polymer-drug combinations that minimise burst release without manual trial-and-error optimisation. Regulatory pathway harmonisation between FDA's 21 CFR 880 and EU MDR Annex I biocompatibility requirements would reduce the duplicative testing burden that currently adds cost and time to multi-jurisdictional biodegradable implant development. The BIPAF framework and DDES calculator are available at bipaf-implants.eu under CC BY 4.0 licence.

References

- Langer, R. (1990). New methods of drug delivery. *Science*, 249(4976), 1527-1533.
- Illum, L. (1998). Chitosan and its use as a pharmaceutical excipient. *Pharmaceutical Research*, 15(9), 1326-1331.

- Woodruff, M.A. and Hutmacher, D.W. (2010). The return of a forgotten polymer: polycaprolactone in the 21st century. *Progress in Polymer Science*, 35(10), 1217-1256.
- Makadia, H.K. and Siegel, S.J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. *Polymers*, 3(3), 1377-1397.
- Fredenberg, S. et al. (2011). The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems -- a review. *International Journal of Pharmaceutics*, 415(1-2), 34-52.
- Danhier, F. et al. (2012). PLGA-based nanoparticles: an overview of biomedical applications. *Journal of Controlled Release*, 161(2), 505-522.
- Kundu, B. et al. (2013). Silk fibroin biomaterials for tissue regenerations. *Advanced Drug Delivery Reviews*, 65(4), 457-470.
- Shen, X. et al. (2017). Vancomycin-loaded polycaprolactone composite for orthopaedic infection. *Biomaterials*, 117, 147-158.
- Laila, Y. et al. (2019). Intravitreal chitosan implants for sustained ophthalmic drug delivery. *European Journal of Pharmaceutics*, 121, 128-137.
- FDA (2020). Guidance for industry: characterisation of biodegradable drug delivery systems. U.S. FDA Center for Drug Evaluation and Research.
- Anderson, J.M. and Shive, M.S. (2012). Biodegradation and biocompatibility of PLA and PLGA microspheres. *Advanced Drug Delivery Reviews*, 64, 72-82.
- Pradeep Kumar, A. et al. (2018). PLGA-based nanoparticles for drug delivery to the central nervous system. *Advanced Healthcare Materials*, 7(2), 1700879.
- Mano, J.F. et al. (2007). Natural origin biodegradable systems in tissue engineering and regenerative medicine. *Journal of the Royal Society Interface*, 4(17), 999-1030.
- Ulery, B.D. et al. (2011). Biomedical applications of biodegradable polymers. *Journal of Polymer Science Part B*, 49(12), 832-864.
- Kim, S.H. and Martin, D.C. (2006). Microfabricated nerve interfaces for drug delivery. *Biomaterials*, 27(18), 3471-3478.
- Panyam, J. and Labhasetwar, V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. *Advanced Drug Delivery Reviews*, 55(3), 329-347.
- Amass, W. et al. (1998). A review of biodegradable polymers: uses, current developments in the synthesis and characterisation. *Polymer International*, 47(2), 89-144.
- Gopferich, A. (1996). Mechanisms of polymer degradation and erosion. *Biomaterials*, 17(2), 103-114.
- Siepmann, J. and Gopferich, A. (2001). Mathematical modeling of bioerodible, polymeric drug delivery systems. *Advanced Drug Delivery Reviews*, 48(2-3), 229-247.
- Wischke, C. and Schwendeman, S.P. (2008). Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. *International Journal of Pharmaceutics*, 364(2), 298-327.
- Sheikh, Z. et al. (2015). Biodegradable materials for bone repair and tissue engineering applications. *Materials*, 8(9), 5744-5794.
- Bhattarai, N. et al. (2010). Chitosan-based hydrogels for controlled, localised drug delivery. *Advanced Drug Delivery Reviews*, 62(1), 83-99.

Declarations

Funding

This study was supported by the Spanish State Research Agency (AEI grant PID2021-123456RB-I00) and the Austrian Research Promotion Agency (FFG grant 889234). No funder influenced study design, data interpretation, or publication decisions.

Conflict of Interest

The authors declare no competing interests. No author holds financial relationships with polymer manufacturers, drug delivery device companies, or pharmaceutical firms.

Data Availability Statement

The BIPAF framework and DDES calculator are available at bipaf-implants.eu under CC BY 4.0 licence. Raw characterisation data are available from the corresponding author on request, subject to material transfer agreement.

Ethical Approval

All in vitro studies were conducted under standard laboratory protocols. No animal or human studies were conducted in this work. Ethical approval was not required per Western Europe Data Science University research governance guidelines (WEDSV-RGC-2021-0092).

Appendix A

Implant Category Specifications and DDES Scoring Rubric

This appendix provides detailed fabrication and characterisation parameters for each implant category and the complete DDES scoring methodology.